Literature DB >> 6599662

Three distinct subtypes of serotonergic receptors mediate the triphasic blood pressure response to serotonin in rats.

H O Kalkman, G Engel, D Hoyer.   

Abstract

In pentobarbitone- or urethane-anaesthetized normotensive rats the triphasic pressure response to serotonin (5-HT): a short-lasting depressor phase with an intense bradycardia, a pressor phase and a prolonged hypotension, was investigated. The highly selective 5-HTM antagonist ICS 205-930 (1 microgram/kg) inhibited the first but not the second or third phase. The 5-HT2 antagonist ketanserin (0.1 mg/kg) inhibited the second but not the first or third phase. Following selective blockade of the pressor component with ketanserin (0.1 mg/kg), the hypotensive potency of eight serotonin receptor agonists was quantified (-log ED50). A correlation (r = 0.75, P less than 0.05) was observed between this parameter and the displacement of the 5-HT1 ligand [3H]-5-HT. It is suggested that the three phases are due to 5-HTM-, 5-HT2- and 5-HT1-receptor activation, respectively.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6599662

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  7 in total

1.  Classification of 5-HT(1A) receptor agonists and antagonists using GA-SVM method.

Authors:  Xue-lian Zhu; Hai-yan Cai; Zhi-jian Xu; Yong Wang; He-yao Wang; Ao Zhang; Wei-liang Zhu
Journal:  Acta Pharmacol Sin       Date:  2011-10-03       Impact factor: 6.150

Review 2.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

Review 3.  Ageing, serotonin and ketanserin.

Authors:  A Breckenridge
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Comparative analysis of two types of 5-hydroxytryptamine receptor mediating vasorelaxation: differential classification using tryptamines.

Authors:  G R Martin; P Leff; D Cambridge; V J Barrett
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-10       Impact factor: 3.000

Review 5.  The role of serotonin in cardiovascular diseases and their treatment.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

Review 6.  Neurally mediated syncope and serotonin reuptake inhibitors.

Authors:  D Samoil; B P Grubb
Journal:  Clin Auton Res       Date:  1995-10       Impact factor: 4.435

7.  Baroreceptor Modulation of the Cardiovascular System, Pain, Consciousness, and Cognition.

Authors:  Heberto Suarez-Roca; Negmeldeen Mamoun; Martin I Sigurdson; William Maixner
Journal:  Compr Physiol       Date:  2021-02-12       Impact factor: 9.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.